Intercept Pharmaceuticals (ICPT) Osake Kurssi

Intercept Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The main competitors of Intercept Pharmaceuticals Inc in the market are AbbVie Inc., Gilead Sciences Inc., and Bristol-Myers Squibb Company.

Intercept Pharmaceuticals Inc is a biopharmaceutical company headquartered in New York, USA. Founded in 2002, Intercept focuses on the development and commercialization of innovative therapeutics to treat progressive liver diseases. The company's primary focus is on developing treatments for non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other liver diseases. Intercept made significant advancements with its flagship drug, Ocaliva, which received regulatory approvals for treating PBC and advanced fibrosis due to NASH. With a dedicated team of researchers and clinical experts, Intercept Pharmaceuticals Inc continues to expand its pipeline and strive for breakthrough treatments in the field of liver diseases.

Intercept Pharmaceuticals Inc has achieved significant milestones in its history. One of the notable achievements is the FDA approval of its drug Ocaliva® (obeticholic acid) in 2016, for the treatment of primary biliary cholangitis (PBC). This approval marked a major breakthrough in the treatment options for PBC patients. Additionally, Intercept Pharmaceuticals Inc has made progress in clinical trials for its drug candidate, OCA, which is being evaluated for the treatment of nonalcoholic steatohepatitis (NASH). The company has also expanded its global presence, actively collaborating with healthcare professionals and researchers to advance liver disease management. Intercept Pharmaceuticals Inc continues to strive for further innovation and development within the pharmaceutical industry.

Intercept Pharmaceuticals Inc is primarily present in the United States and Europe. As a renowned pharmaceutical company, Intercept has established its presence in major countries and regions within these continents. The company has successfully expanded its operations and is actively engaged in conducting clinical trials, seeking regulatory approvals, and commercializing its innovative therapeutics in these markets. With its headquarters located in New York City, Intercept Pharmaceuticals Inc continues to thrive and enhance its footprint in the healthcare industry across various countries and regions, providing innovative solutions and improving patient outcomes.

Intercept Pharmaceuticals Inc is a company known for its strong values and corporate philosophy. The company is committed to delivering innovative treatments and solutions for patients with liver and other metabolic diseases. Intercept Pharmaceuticals Inc places a high emphasis on scientific rigor, integrity, and patient-focused approaches. With an unwavering dedication to quality and excellence, the company strives to provide breakthrough therapies to improve the lives of individuals worldwide. By continuously pushing boundaries and investing in cutting-edge research, Intercept Pharmaceuticals Inc is shaping the future of medical advancements in hepatology and beyond.

20 analyytikkoa arvioi tällä hetkellä Intercept Pharmaceuticals-osaketta: 7 suosittaa ostoa, 13 pitoa ja 0 myyntiä.

Intercept Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Intercept Pharmaceuticals-osake (ICPT) on listattuna 4 pörssissä, muun muassa: NASDAQ (ICPT), Frankfurt (I4P.F), München (I4P.MU), Düsseldorf (I4P.DU).

Intercept Pharmaceuticals Inc. is a global biotechnology company focused on the discovery, development, and commercialization of therapeutics for the treatment of chronic liver diseases and other metabolic disorders. The company was founded in 2002 and is headquartered in New York City. Intercept's business strategy is based on identifying and developing innovative therapy approaches for treating various diseases that represent significant medical needs worldwide. The company's product portfolio focuses on the development of drugs specifically targeting the enzyme that is the main cause of liver diseases and other metabolic disorders. Intercept Pharmaceuticals' flagship product is Ocaliva (Obeticholic Acid), an FXR agonist for the treatment of primary biliary cholangitis (PBC). PBC is a rare chronic inflammatory liver disease in which the immune system attacks and destroys the bile ducts in the liver. Ocaliva is the first medication approved by the FDA for the treatment of PBC after choleretic therapy. In addition to Ocaliva, Intercept Pharmaceuticals is also working on the development of other drugs for the treatment of liver diseases and other metabolic disorders. Another promising product is INT-767, a dual FXR/TGR5 agonist being developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Intercept Pharmaceuticals is also pursuing a comprehensive clinical development strategy to find new applications and indications for its products. The company collaborates closely with patient organizations, universities, and companies to support the research of liver diseases and other metabolic disorders. Intercept Pharmaceuticals also has a strong presence in the global market. The company has entered into distribution partnerships with leading pharmaceutical companies worldwide to bring its products to market faster and more reliably. In the United States, Ocaliva is distributed in collaboration with the Japanese pharmaceutical company Sumitomo Dainippon Pharma. In Europe, Intercept Pharmaceuticals works with the French company Genfit. In addition to its product development and distribution strategy, Intercept Pharmaceuticals is also heavily involved in research and development. The company invests significant resources in researching new technologies and therapeutics to expand its product range and identify new applications. Intercept Pharmaceuticals collaborates closely with leading universities and research institutions worldwide to advance its research agenda. Overall, Intercept Pharmaceuticals' business model aims to develop and bring innovative therapies for the treatment of liver diseases and other metabolic disorders to market. The company pursues a comprehensive development strategy and collaborates closely with other companies and institutions to drive innovation. Intercept Pharmaceuticals is on a promising growth trajectory and has the potential to become a leading provider of therapeutics for liver diseases and other metabolic disorders.

Liikevaihtoa ei voida laskea Intercept Pharmaceuticals:lle tällä hetkellä.

Voittoa ei voida laskea Intercept Pharmaceuticals:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Intercept Pharmaceuticals:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Intercept Pharmaceuticals:lle tällä hetkellä.

Intercept Pharmaceuticals:n Eulpool-laatuscore on 3/10.

Intercept Pharmaceuticals:n ISIN on US45845P1084. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Intercept Pharmaceuticals:n WKN on A1J5U0. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Intercept Pharmaceuticals:n ticker on ICPT. Tämä pörssinoteeraus käytetään Intercept Pharmaceuticals-osakkeiden kauppaan pörssissä.